M Pharmaceutical Inc.
CNSX : MQ
OTCQB : MPHMF
FRANKFURT : T3F2

M Pharmaceutical Inc.

August 17, 2015 14:25 ET

M Pharmaceutical and Rishena Enter Into Manufacturing Supply Agreement for Production of Trimtec Gastric Stimulation Device

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 17, 2015) - M Pharmaceutical, Inc. (CSE:MQ)(OTCQB:MPHMF)(FRANKFURT:T3F2), (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological disorders, announced today that it has entered into a manufacturing supply agreement with Rishena Co., Ltd., of Changzhou, China, to manufacture the Company's Trimtec gastric functional neurostimulation device. Under the terms of the agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharmaceutical for the North and South American markets. The devices will be fully programmable and rechargeable through an abdominal belt. Rishena commits, at its expense, to obtain ISO 13485 certification1 for Trimtec manufacturing prior to the Company's commercial launch of Trimtec.

"Our agreement with Rishena is an important step forward in the development of Trimtec for the North and South American markets," said Dr. Martin Mintchev, the President and CEO of M Pharma. "We are delighted to collaborate with an experienced and respected medical device manufacturer such as Rishena and look forward to successful collaboration with them."

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal functional neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

About Rishena Co., Ltd.

Rishena Co., Ltd. is a venture-capital backed medical device company located in the Changzhou, China Hi-Tech Development Zone. Rishena is focused on the development, production, and sales of innovative implantable nerve stimulation products.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

1 ISO 13485 certification is considered the foremost internationally-accepted model to demonstrate regulatory compliance and quality manufacturing in the medical device industry. ISO 13845 aligns to the manufacturing quality principles required by Health Canada and U.S. FDA for marketing a medical device in these countries and can be considered a significant step toward full compliance with U.S. Quality System Regulations.

Contact Information